ZPDH:F:F-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 35.715

Change

+0.09 (+0.24)%

Market Cap

USD 0.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.66 (-1.27%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.34 (-0.24%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.69 (-1.20%)

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.19 (-1.20%)

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

-2.80 (-1.20%)

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

-0.20 (-0.20%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.05 (-0.63%)

USD 46.87B
0ZC:F Zscaler Inc

-0.05 (-0.02%)

USD 37.92B
BSND:F Danone SA

-0.20 (-1.37%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing ZPDH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.66% 10% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.66% 11% F 30% F
Trailing 12 Months  
Capital Gain -11.59% 12% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.59% 11% F 32% F
Trailing 5 Years  
Capital Gain 36.58% 49% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.58% 50% F 41% F
Average Annual (5 Year Horizon)  
Capital Gain 11.42% 77% C+ 69% C-
Dividend Return 11.42% 75% C 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.43% 57% F 88% B+
Risk Adjusted Return 99.85% 91% A- 93% A
Market Capitalization 0.40B 55% F 45% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike